BioAtla introduces GigaMab™ Fully Human Antibody Platform (October 7, 2010)

Molecular Response Announced Today the Appointment of Cyrus K. Mirsaidi to Chief Executive Officer (September 20, 2010)

Molecular Response launches west coast operations (July 6, 2010)

FEMTA Pharmaceuticals and Loza enter into Manufacturing Agreement (December 15, 2009)

PPD Completes Acquisition of BioDuro ( December 03, 2009 )

PPD to Acquire BioDuro ( November 19, 2009 )

Shipping Drug R&D Abroad ( October 19, 2009 )

CROs expand business to fight crisis ( July 03, 2009 )
Beijing-based CRO BioDuro and AstraZeneca announced a major deal to expand their research collaboration to optimise discovery research for respiratory and inflammation indications.

BioDuro to work with Roche on discovery chemistry ( April 8, 2009 )
Just weeks after expanding its relationship with AstraZeneca, China CRO BioDuro has been asked by Swiss drug maker Roche to help with its discovery phase R&D program.

BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services ( April 6, 2009 )
BioDuro announced today that they have entered into a strategic partnership with Roche to support discovery phase research efforts at Roche’s global research sites.

AstraZeneca and BioDuro expand discovery contract ( March 25, 2009 )
The Chinese unit of US contract drug discovery firm BIoDuro says that AstraZeneca has expanded its relationship with the firm to include the optimization of discovery research operations focused on drugs for respiratory and inflammatory disease.

BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications ( March 23, 2009 )
BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.

BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory ( March 23, 2009 )
BioDuro and AstraZeneca expand collaboration to optimize discovery research for Respiratory and Inflammation indications.

BioDuro Expand Discovery Pact with AstraZeneca ( March 23, 2009 )
BioDuro and AstraZeneca have expanded their discovery research collaboration for respiratory and inflammation indiciations.

BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications ( March 23, 2009 )
BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.

BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indication ( March 23, 2009 )
BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.

Fully Integrated Research Service is the future ( April 1, 2009 )
The world is a different place now than it was three months ago or even six months ago.  Even without the financial crisis that has crippled the global economy; the pharmaceutical industry was already in disarray as news of large layoffs from the major paharma spread across North America and Europe.

Cautious Optimism Prevails for Chinese Biotechnology ( January 1, 2009 )
That combination of factors is resulting in successes. BioDuro, a multinational life science outsourcing company with labs in Beijing, is a prime example. With a staff of 540, one-quarter of its scientists hold doctoral degrees. It has worked with some 40 biopharmaceutical companies, focusing on the hit-to-clinic stage, according to Yun He, Ph.D., vp of research for BioDuro.